AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 53(5), 1995, pp. 507-510
Copyright © 1995 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Consroe, P.
Right arrow Articles by Landon, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Consroe, P.
Right arrow Articles by Landon, J. T.

Comparison of a New Ovine Antigen Binding Fragment (Fab) Antivenin for United States Crotalidae with the Commercial Antivenin for Protection against Venom-Induced Lethality in Mice

P. Consroe, N. B. Egen, F. E. Russell, K. Gerrish, D. C. Smith, A. Sidki AND J. T. Landon
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona; Department of Chemical Pathology, Medical College of St. Bartholomew's Hospital, London, United Kingdom

Snake venom poisoning is a medical emergency requiring immediate attention and the exercise of considerable judgment. Of the estimated 8,000 bites inflicted by venomous snakes in the United States each year, approximately 6,000 are treated with commercial antivenin. The only commercially available antivenin for North American Crotalidae envenomation is Antivenin (Crotalidae) Polyvalent (equine origin) (ACP; Wyeth Laboratories, Philadelphia, PA). A common complication is the high incidence of hypersensitivity reactions, occurring in more than 75% of patients treated with ACP. To minimize these side effects, a novel, affinity-purified, antigen binding fragment (Fab) antivenom (FabAV) for Crotalidae venom poisoning has been produced from the sera of sheep. The new product is Antivenin Polyvalent Crotalid (Ovine) Fab (CrotabTM; Therapeutic Antibodies, Inc., Nashville, TN). The current report compares the potencies in mice of FabAV and ACP against venom-induced lethality. The results indicate that FabAV is 3.1–9.6 times more potent than ACP for the prevention of lethality of the nine United States venoms tested. For one of the venoms, Crotalus viridis helleri, FabAV was efficacious while ACP was not.




This article has been cited by other articles:


Home page
 NEJMHome page
B. S. Gold, R. C. Dart, and R. A. Barish
Bites of Venomous Snakes
N. Engl. J. Med., August 1, 2002; 347(5): 347 - 356.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Society of Tropical Medicine and Hygiene.